SPYRE THERAPEUTICS, INC. Research and Development Expense
SPYRE THERAPEUTICS, INC. (SYRE) reported Research and Development Expense of $13.78 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-05-11
- SPYRE THERAPEUTICS, INC. research and development expense for the quarter ending 2023-03-31 was $13.78M, a 18.86% decline year-over-year.
- SPYRE THERAPEUTICS, INC. research and development expense for the quarter ending 2022-12-31 was $14.25M, a 15.08% decline year-over-year.
- SPYRE THERAPEUTICS, INC. research and development expense for the quarter ending 2022-09-30 was $11.98M, a 19.36% decline year-over-year.
- SPYRE THERAPEUTICS, INC. research and development expense for the quarter ending 2022-06-30 was $15.37M, a 13.21% increase year-over-year.
- SPYRE THERAPEUTICS, INC. research and development expense for fiscal 2022 was $58.58M, a 2.65% increase from fiscal 2021.
- SPYRE THERAPEUTICS, INC. research and development expense for fiscal 2021 was $57.07M, a 4.31% decline from fiscal 2020.
- SPYRE THERAPEUTICS, INC. research and development expense for fiscal 2020 was $59.64M, a 7.68% decline from fiscal 2019.
- SPYRE THERAPEUTICS, INC. research and development expense for fiscal 2019 was $64.60M, a 75.93% increase from fiscal 2018.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-03-31 | $13.78M 10-Q · filed 2023-05-11 | $28.03M derived: sum of 2 quarters · filed 2023-05-11 | $40.00M derived: sum of 3 quarters · filed 2023-05-11 | $55.38M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | $14.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $26.23M derived: sum of 2 quarters · filed 2023-03-02 | $41.60M derived: sum of 3 quarters · filed 2023-03-02 | $58.58M 10-K · filed 2023-03-02 |
| 2022-09-30 | $11.98M 10-Q · filed 2022-11-03 | $27.35M derived: sum of 2 quarters · filed 2022-11-03 | $44.33M 10-Q · filed 2022-11-03 | $61.11M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-06-30 | $15.37M 10-Q · filed 2022-08-04 | $32.35M 10-Q · filed 2022-08-04 | $49.13M derived: sum of 3 quarters · filed 2023-05-11 | $63.99M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-03-31 | $16.98M 10-Q · filed 2023-05-11 | $33.76M derived: sum of 2 quarters · filed 2023-05-11 | $48.61M derived: sum of 3 quarters · filed 2023-05-11 | $62.19M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $16.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $31.64M derived: sum of 2 quarters · filed 2023-03-02 | $45.21M derived: sum of 3 quarters · filed 2023-03-02 | $57.07M 10-K · filed 2023-03-02 |
| 2021-09-30 | $14.85M 10-Q · filed 2022-11-03 | $28.43M derived: sum of 2 quarters · filed 2022-11-03 | $40.29M 10-Q · filed 2022-11-03 | $56.04M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $13.58M 10-Q · filed 2022-08-04 | $25.43M 10-Q · filed 2022-08-04 | $41.19M derived: sum of 3 quarters · filed 2023-03-02 | $53.64M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $11.86M 10-Q · filed 2022-05-05 | $27.61M derived: sum of 2 quarters · filed 2023-03-02 | $40.06M derived: sum of 3 quarters · filed 2023-03-02 | $56.93M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $15.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $28.21M derived: sum of 2 quarters · filed 2023-03-02 | $45.08M derived: sum of 3 quarters · filed 2023-03-02 | $59.64M 10-K · filed 2023-03-02 |
| 2020-09-30 | $12.45M 10-Q · filed 2021-11-04 | $29.32M derived: sum of 2 quarters · filed 2021-11-04 | $43.88M 10-Q · filed 2021-11-04 | $61.45M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | $16.87M 10-Q · filed 2021-08-05 | $31.43M 10-Q · filed 2021-08-05 | $49.00M derived: sum of 3 quarters · filed 2022-03-08 | $66.84M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $14.56M 10-Q · filed 2021-05-10 | $32.13M derived: sum of 2 quarters · filed 2022-03-08 | $49.97M derived: sum of 3 quarters · filed 2022-03-08 | $64.77M derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | $17.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $35.41M derived: sum of 2 quarters · filed 2022-03-08 | $50.21M derived: sum of 3 quarters · filed 2022-03-08 | $64.60M 10-K · filed 2022-03-08 |
| 2019-09-30 | $17.84M 10-Q · filed 2020-11-05 | $32.65M derived: sum of 2 quarters · filed 2020-11-05 | $47.03M 10-Q · filed 2020-11-05 | $58.83M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $14.81M 10-Q · filed 2020-08-10 | $29.20M 10-Q · filed 2020-08-10 | $40.99M derived: sum of 3 quarters · filed 2021-03-18 | $49.92M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $14.39M 10-Q · filed 2020-05-07 | $26.19M derived: sum of 2 quarters · filed 2021-03-18 | $35.12M derived: sum of 3 quarters · filed 2021-03-18 | $44.24M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $11.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $20.73M derived: sum of 2 quarters · filed 2021-03-18 | $29.85M derived: sum of 3 quarters · filed 2021-03-18 | $36.72M 10-K · filed 2021-03-18 |
| 2018-09-30 | $8.93M 10-Q · filed 2019-11-06 | $18.05M derived: sum of 2 quarters · filed 2019-11-06 | $24.92M 10-Q · filed 2019-11-06 | $30.71M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $9.12M 10-Q · filed 2019-08-06 | $15.99M 10-Q · filed 2019-08-06 | $21.78M derived: sum of 3 quarters · filed 2020-02-24 | $28.02M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $6.87M 10-Q · filed 2019-05-07 | $12.66M derived: sum of 2 quarters · filed 2020-02-24 | $18.90M derived: sum of 3 quarters · filed 2020-02-24 | $24.73M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $12.03M derived: sum of 2 quarters · filed 2020-02-24 | $17.86M derived: sum of 3 quarters · filed 2020-02-24 | $22.82M 10-K · filed 2020-02-24 |
| 2017-09-30 | $6.24M 10-Q · filed 2018-11-08 | $12.07M derived: sum of 2 quarters · filed 2018-11-08 | $17.02M 10-Q · filed 2018-11-08 | $21.76M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $5.83M 10-Q · filed 2018-08-09 | $10.78M 10-Q · filed 2018-08-09 | $15.53M derived: sum of 3 quarters · filed 2019-03-07 | $20.91M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $4.95M 10-Q · filed 2018-05-08 | $9.69M derived: sum of 2 quarters · filed 2019-03-07 | $15.07M derived: sum of 3 quarters · filed 2019-03-07 | $19.50M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $4.74M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $10.13M derived: sum of 2 quarters · filed 2019-03-07 | $14.55M derived: sum of 3 quarters · filed 2019-03-07 | $18.14M 10-K · filed 2019-03-07 |
| 2016-09-30 | $5.38M 10-Q · filed 2017-11-07 | $9.80M derived: sum of 2 quarters · filed 2017-11-07 | $13.40M 10-Q · filed 2017-11-07 | $17.37M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-06-30 | $4.42M 10-Q · filed 2017-08-09 | $8.02M 10-Q · filed 2017-08-09 | $11.98M derived: sum of 3 quarters · filed 2018-03-13 | $15.11M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-03-31 | $3.60M 10-Q · filed 2017-05-09 | $7.56M derived: sum of 2 quarters · filed 2018-03-13 | $10.69M derived: sum of 3 quarters · filed 2018-03-13 | $13.43M derived: sum of 4 quarters · filed 2018-03-13 |
| 2015-12-31 | $3.97M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $7.09M derived: sum of 2 quarters · filed 2018-03-13 | $9.83M derived: sum of 3 quarters · filed 2018-03-13 | $11.45M 10-K · filed 2018-03-13 |
| 2015-09-30 | $3.13M 10-Q · filed 2016-11-09 | $5.87M derived: sum of 2 quarters · filed 2016-11-09 | $7.49M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $2.74M 10-Q · filed 2016-08-09 | $4.36M 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $1.62M 10-Q · filed 2016-05-19 | |||
| 2014-12-31 | $6.83M 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |